17,261 trials
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Type 2 Diabetes
Primary: Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population — -0.52; -0.33; -0.24; -0.34 Percent of Hemoglobin
Alzheimer Disease · Amyloid Beta-Protein
Primary: Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth — 79.49…
Colon Cancer · Rectal Cancer
Primary: Incidence of Complete Resection — 13 participants
Stem Cell Transplantation · Leukemia
Primary: Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor — 1; 4; 7; 4 participants
Tobacco Use Cessation
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 6; 8 participants
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1
Asthma
Primary: Baseline Concentration (C0) of Labeled Epinephrine Total Epinephrine — 9.3; 8.9; 7.8 pg/mL
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Primary: Best Tumor Response (Core) — 0; 1; 49; 49 participants
Obsessive-Compulsive Disorder · Autism Spectrum Disorder · Autism
Primary: Much/Very Much Improved on Clinical Global Impressions - Improvement Score (CGI-I) — 3; 4 participants — p=0.959
Breast Cancer
Primary: The Quantity of Leukocytes and Neutrophils in the Blood of Patients — 8.1; 7.2; 6.6; 4.8 10^9 cells/L
Solid Tumors
Primary: Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Irinotecan and Its Metabolite SN-38 From Time Zero to Infinity [AUC(0-∞)] in Cycle 1…
Liver Cancer
Primary: Percentage of Participants With Progression-free Survival (PFS) — 35.3 percentage of participants
Gastroesophageal Cancer · Gastric Cancer
Primary: Progression Free Survival — 7.8 months
Head and Neck Cancer
Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013 — 76; 68 participants